News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
354,404 Results
Type
Article (27122)
Company Profile (150)
Press Release (327132)
Section
Business (103062)
Career Advice (1294)
Deals (16967)
Drug Delivery (73)
Drug Development (42415)
Employer Resources (152)
FDA (9036)
Job Trends (8828)
News (174296)
Policy (15762)
Tag
Academia (1984)
Alliances (29442)
Alzheimer's disease (783)
Approvals (8980)
Artificial intelligence (88)
Bankruptcy (96)
Best Places to Work (7338)
Biosimilars (54)
Biotechnology (96)
Breast cancer (69)
Cancer (540)
Career advice (1140)
Cell therapy (128)
Clinical research (33568)
Collaboration (238)
Compensation (69)
COVID-19 (1369)
C-suite (55)
Cystic fibrosis (64)
Data (574)
Diabetes (81)
Diagnostics (3439)
Earnings (30023)
Employer resources (133)
Events (51048)
Executive appointments (187)
FDA (9347)
Funding (190)
Gene therapy (107)
GLP-1 (358)
Government (2358)
Healthcare (10230)
Infectious disease (1418)
Inflammatory bowel disease (84)
Interviews (192)
IPO (7152)
Job creations (1727)
Job search strategy (1005)
Layoffs (170)
Legal (2913)
Lung cancer (92)
Manufacturing (105)
Medical device (6724)
Medtech (6728)
Mergers & acquisitions (9925)
Metabolic disorders (229)
Neuroscience (957)
NextGen Class of 2024 (3739)
Non-profit (3457)
Northern California (731)
Obesity (137)
Opinion (113)
People (34874)
Phase I (9602)
Phase II (14457)
Phase III (12399)
Pipeline (132)
Postmarket research (1379)
Preclinical (4155)
Press Release (62)
Radiopharmaceuticals (122)
Rare diseases (136)
Real estate (3527)
Recruiting (58)
Regulatory (11199)
Research institute (1751)
Resumes & cover letters (165)
Southern California (611)
Startups (2523)
United States (6692)
Vaccines (259)
Weight loss (103)
Date
Today (140)
Last 7 days (478)
Last 30 days (1796)
Last 365 days (21822)
2024 (18613)
2023 (24112)
2022 (30852)
2021 (33503)
2020 (31133)
2019 (27034)
2018 (20224)
2017 (18260)
2016 (17613)
2015 (19821)
2014 (14584)
2013 (11973)
2012 (12590)
2011 (13025)
2010 (11832)
Location
Africa (515)
Arizona (78)
Asia (31308)
Australia (4686)
California (1585)
Canada (622)
China (137)
Colorado (59)
Connecticut (79)
Europe (51067)
Florida (228)
Georgia (69)
Illinois (171)
Indiana (151)
Maryland (281)
Massachusetts (1297)
Michigan (82)
Minnesota (141)
New Jersey (545)
New York (520)
North Carolina (446)
Northern California (731)
Ohio (82)
Pennsylvania (360)
South America (684)
Southern California (611)
Texas (196)
Washington State (124)
354,404 Results for "tiziana life sciences ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
Tiziana Life Sciences, Ltd. today announced that the U.S. Food and Drug Administration (FDA) has allowed intranasal foralumab to be used under an Expanded Access (EA) IND in its first patient with moderate Alzheimer’s disease.
June 26, 2024
·
3 min read
Pharm Country
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
Tiziana Life Sciences, Ltd. announced it has submitted an FDA request to obtain Orphan Drug Designation for intranasal foralumab for the treatment of non-active secondary progressive Multiple Sclerosis.
May 13, 2024
·
3 min read
Pharm Country
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
Tiziana Life Sciences, Ltd. announced that Howard L. Weiner, M.D., Chairman of Tiziana’s Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham healthcare system, is being honored with the prestigious “Giants of MS” award for his outstanding contributions in the area of multiple sclerosis research.
May 30, 2024
·
5 min read
Pharm Country
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has received acceptance of its submission for intranasal foralumab to receive Fast Track Designation approval for the treatment of non-active, secondary-progressive multiple sclerosis (na-SPMS) to the U.S. Food and Drug Administration (FDA).
June 11, 2024
·
3 min read
Pharm Country
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”) today announced it has been honored with an invitation to apply for a prestigious grant from the ALS Association head by James Berry, MD, MPH and Suma Babu, MBBS, MS, the Director and Co-Director of the Neurological Clinical Research Institute (NCRI) at Mass General Hospital, a founding member of Mass General Brigham.
June 4, 2024
·
5 min read
Pharm Country
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
Tiziana Life Sciences, Ltd., a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, announced the qualitative results for all 10 non-active Secondary Progressive Multiple Sclerosis patients enrolled in the intermediate-size patient population Expanded Access Program receiving foralumab for at least six months.
June 6, 2024
·
3 min read
Pharm Country
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”) today announced for the first time, quantitative data showing improvement in White Matter Z-scores measured from PET images taken at 3 months in nasal foralumab treated patients with non-active secondary progressive multiple sclerosis (na-SPMS).
April 25, 2024
·
4 min read
Press Releases
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
October 30, 2024
·
8 min read
Pharm Country
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
Tiziana Life Sciences, Ltd. today announced additional positive clinical results from its intermediate sized Expanded Access Program (EAP) for non-active secondary progressive multiple sclerosis (na-SPMS) patients.
April 22, 2024
·
6 min read
Pharm Country
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
Tiziana Life Sciences, Ltd. today announces a platform presentation titled, “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS” at the Annual Meeting of the American Academy of Neurology in Denver, Colorado.
April 18, 2024
·
4 min read
1 of 35,441
Next